Therapies for Pulmonary Arterial Hypertension in Children
Therapies for Pulmonary Arterial Hypertension in Children
Advances in the treatment of pulmonary arterial hypertension (PAH) over the past 20 years have made a significant impact on the course of this disease in infants and children. The approval of epoprostenol by the Food and Drug Administration (FDA) on September 21, 1995 and inhaled nitric oxide on December 23, 1999 introduced therapies for stabilization and improved early survival. Development of alternative agents has provided more options for long-term management. These therapies include other prostanoids (iloprost and treprostinil), as well as the endothelin antagonist bosentan and sildenafil, a phosphodiesterase type 5 (PDE 5) inhibitor. This issue of the newsletter will review several recent PAH studies, as well as preliminary safety and efficacy data for two new once-daily treatments, ambrisentan and tadalafil.
Introduction
Advances in the treatment of pulmonary arterial hypertension (PAH) over the past 20 years have made a significant impact on the course of this disease in infants and children. The approval of epoprostenol by the Food and Drug Administration (FDA) on September 21, 1995 and inhaled nitric oxide on December 23, 1999 introduced therapies for stabilization and improved early survival. Development of alternative agents has provided more options for long-term management. These therapies include other prostanoids (iloprost and treprostinil), as well as the endothelin antagonist bosentan and sildenafil, a phosphodiesterase type 5 (PDE 5) inhibitor. This issue of the newsletter will review several recent PAH studies, as well as preliminary safety and efficacy data for two new once-daily treatments, ambrisentan and tadalafil.
Source...